Fate Therapeutics Inc. (FATE)

Healthcare | Biotechnology & Pharma Research

Fate Therapeutics Inc. (FATE) Premium Coverage

52 Stocks to buy right now

Join now and be among the first to discover Stock Ideas

Get the Stocks!

Please wait...

Annual
Quarterly

Please wait...

Please wait...

Please wait...

Please wait...

About The Company

Business: Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

IPO Date: 01-Oct-2013

Founder, CEO, Pres & Director: Mr. J. Scott Wolchko

Chief Financial Officer: Mr. Edward J. Dulac III

Listing: NASDAQ: FATE

Country: United States

Headquarters: San Diego, CA

Website: https://www.fatetherapeutics.com

Key Facts

Market cap: $2,536.51 Mln

Revenue (TTM): $63.12 Mln

Earnings (TTM): $-232.75 Mln

Cash: $573.77 Mln

Total Debt: $113.52 Mln

Insider's Holding: 1.42%

Liquidity: Low

52 Week range: $17.11 - 97.43

Shares outstanding: 96,629,104

10 Years Aggregate:

CFO: $-460.12 Mln
EBITDA: $-687.87 Mln
Net Profit: $-717.71 Mln

Stock Performance

Trailing
Annual

Time Period	Fate Therapeutics (FATE)	S&P BSE Sensex*	S&P Small-Cap 600*
YTD	-57.70	-8.97	-18.40
1 month	4.96	-3.38	-8.42
3 months	-34.87	-7.93	-14.06
1 Year	-70.73	0.55	-17.64
3 Years	6.59	10.41	6.75
5 Years	50.84	11.45	6.18
10 Years	--	12.05	10.23

As on 28-Jun-2022 *As on 29-Jun-2022

Year	Fate Therapeutics (FATE)	S&P Small-Cap 600	S&P BSE Sensex
2021	-35.65	25.27	21.99
2020	364.64	9.57	15.75
2019	52.53	20.86	14.38
2018	109.14	-9.70	5.87
2017	143.43	11.73	27.91
2016	-25.52	24.74	1.95
2015	-33.00	-3.36	-5.03